Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent nab-paclitaxel/carboplatin and thoracic radiotherapy for inoperable stage III squamous cell lung cancer
ChiCTR1800018674Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Dec 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Pulmonary squamous cell carcinoma, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Progression-free survival. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1800018674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018674.